PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-139.60%
Negative net income growth while CRVO stands at 27.02%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
0.49%
D&A growth of 0.49% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
637.66%
SBC growth well above CRVO's 6.95%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-41.30%
Negative yoy working capital usage while CRVO is 100.00%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.30%
Both reduce yoy usage, with CRVO at -100.00%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative yoy CFO while CRVO is 51.63%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Issuance growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.